Gilead's rejected patent application highlights Section 3(d) uncertainties Nearly two years after the Novartis decision, questions about India's Section 3(d) remain By Peter Leung January 23 2015
India’s Section 3(d) strikes again The India patent controller has rejected Gilead’s sofosbuvir patent application, citing the controversial Section 3(d) of the Patents Act By Peter Leung January 15 2015
India releases first draft of National IP Rights Policy India’s Department of Industrial Promotion and Policy (DIPP) is seeking public comments on the first draft of the National IP Rights Policy By Peter Leung January 06 2015
